Comment on "Consolidation Osimertinib Versus Durvalumab following Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC". Chen CY, Wang GS, Wei JC. J Thorac Oncol 2024;19:e6-e7.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Chen CY, Wang GS, Wei JC. Comment on "Consolidation Osimertinib Versus Durvalumab following Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC". J Thorac Oncol 2024;19:e6-e7.
PMID: 38719427